Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 21 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 10793636

    Anti-CD73 antibodies

    Corvus Pharmaceuticals, Inc. · Granted Oct 6, 2020 · Expires Oct 1, 2040

    granted

  2. US 10786552

    Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

    Nektar Therapeutics · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted

  3. US 10787501

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted

  4. US 10781255

    Anti-CD83 antibodies and use thereof

    The Regents of the University of California · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted

  5. US 10772972

    Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted

  6. US 10758613

    Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted

  7. US 10752656

    Anti-microbial supramolecular structures

    Northwestern University · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted

  8. US 10752702

    Anti-TIE2 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted

  9. US 10752701

    Stabilized formulations containing anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted

  10. US 10752699

    Anti-APOBEC3 antibodies and methods of making and using

    Regents of the University of Minnesota · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted

  11. US 10745481

    Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted

  12. US 10744116

    Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas

    The Regents of the University of California · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted

  13. US 10738123

    Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia

    The Regents of the University of Colorado, a Body Corporate · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted

  14. US 10738113

    Anti-IL-2 antibodies and compositions and uses thereof

    The Regents of the University of California · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted

  15. US 10738112

    Anti-human interleukin-17A monoclonal antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted

  16. US 10738116

    Dual specific anti-CD22-anti-CD19 chimeric antigen receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted

  17. US 10738126

    Anti-GITR antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted

  18. US 10738081

    Peptide with anti-obesity and anti-diabetes activity and use thereof

    CAREGEN CO., LTD. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted

  19. US 10736976

    Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted

  20. US 10738124

    Anti-EGFRvIII antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted

  21. US 10729651

    Sustained release formulation of a non-steroidal anti-inflammatory drug

    Pacira Pharmaceuticals, Inc. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted

  22. US 10729768

    Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

    TG Therapeutics, Inc. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted

  23. US 10730949

    Method of treating PVNS with anti-CSF1R antibodies

    Five Prime Therapeutics, Inc. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted

  24. US 10730944

    Anti-CD8 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.